PDCD1 and hepatocellular carcinoma: A phase II/III study assessed the efficacy of PD-1 inhibitor sintilimab plus IBI305, a bevacizumab (VEGF monoclonal antibody) biosimilar, versus sorafenib, as a first-line therapy for unresectable HBV-associated HCC.